A consortium of JGC, Technip Energies and Samsung Heavy Industries has launched bidding for the module work on a second floating liquefied natural gas (FLNG) unit set for deployment offshore ...
SAN ANTONIO — More than $26 million in grant funding is being distributed to support infrastructure projects in military communities across Texas, with a portion earmarked for San Antonio. Greg Abbott ...
Vestal Point acquired 4,500,000 shares of Terns Pharmaceuticals in the fourth quarter. The quarter-end position value increased by $181.80 million as a result of this purchase, which created a new ...
BRUSSELS, March 17, 2026 /PRNewswire/ -- Today, Advanced Biotech for Sustainability (AB4S), a cross-sector coalition that's committed to unlocking the full environmental potential of advanced ...
Harbour BioMed is setting sail as the Solstice begins, riding the waves of biobucks potential that could reach heights up to $1.1 billion. Newly formed Solstice Oncology has inked an exclusive ...
LSU Tigers quarterback Sam Leavitt was declared to be the most impactful transfer portal addition in college football following his success at Arizona State. Arizona State quarterback transfer Sam ...
A man will spend 20 years in prison after he was found guilty of attempted manslaughter and attempted armed robbery in November of 2025. Victim’s attorney claims ChatGPT aided accused Florida State ...
Basquevolt, the Basque solid-state battery initiative whose shareholders include the Basque Government, Iberdrola, CIE Automotive, Enagás, EIT InnoEnergy, CDTI (through Innvierte), and CIC energiGUNE, ...
The MarketWatch News Department was not involved in the creation of this content. Allele will generate mRNA reprogrammed cGMP iPSC lines; conduct R&D to differentiate iPSC into liver cells including ...
Allele will generate mRNA reprogrammed cGMP iPSC lines; conduct R&D to differentiate iPSC into liver cells including hepatocytes, cholangiocytes, endothelial progenitors, hepatic stellate cells, etc.; ...
Some of the best-selling drugs in the world are facing a loss of exclusivity in key jurisdictions in the upcoming years in what the sector calls "the patent cliff." The need for pharma to top up their ...